+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Implantable Cardioverter Defibrillators Market 2019-2025

  • ID: 4969070
  • Report
  • January 2020
  • Region: Global
  • Orion Market Research Private Limited
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott Laboratories, Inc.
  • Biotronik SE & Co. KG
  • Cintas Corp.
  • Defibtech, LLC
  • General Electric Co.
  • Koninklijke Philips N.V.
  • MORE
Implantable Cardioverter Defibrillators (ICD)s are battery-powered devices placed under the skin for keeping a track of heart rate. It has been proved quite useful in preventing sudden death in patients suffering from sustained ventricular tachycardia or fibrillation. ICD holds a critical role in preventing cardiac arrest in high-risk patients who are more prone to life-threatening ventricular arrhythmias. In this process, ICD is connected through thin wires with the patient's heart.

The device delivers an electric shock to restore a normal heartbeat in case of an abnormal heart rhythm, if patient's heart is beating chaotically and much too fast. Though ICDs have demonstrated clear life-saving benefits; concerns about patient acceptance along with psychological adjustment to the ICD have been the focus of much research.

As per researchers, the Quality of Life (QoL) of ICD patients can be better than that of those taking anti-arrhythmic medications. Usually, ICDs are composed of an ICD generator and wires; the first component consists of a programmable software, computer chip or circuitry with RAM (memory), a capacitor and a battery. There are two type of ICDS namely, Transvenous (TV) patients are vulnerable to complications such as fractures, which can turn to inappropriate therapy and infections. Additionally, a device-related infection rate generally varies between 0.67% and 1.49% over a 3 to 12-month follow-up. Moreover, mechanical lead failures can arouse from hardware malfunction, which can further result in inappropriate shocks, over sensing, and inability to deliver appropriate therapy. Furthermore, long-term lead failure rates up to 20% have been reported with Transvenous defibrillators.

Subcutaneous ICD is alternative novel technology used to limit complications associated with transvenous implantable cardioverter-defibrillator. Traditionally, S-ICD was used in patients with difficult venous access. As a result, congenital heart disease patients with venous anomalies are considered good candidates for S-ICD. Additionally, patients who are expected to outlive the life expectancy of their TV leads and requiring device extractions later in life can be ideal for S-ICD. It may also be used in patients with channelopathies or those who undergo renal replacement therapies and require chronic venous access.

Research Methodology

The market study of the Implantable Cardioverter Defibrillators market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors.

Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.
The report is intended for medical device manufacturing companies, distributors and suppliers, and other related companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Implantable Cardioverter Defibrillators Market Research and Analysis by Product
2. Implantable Cardioverter Defibrillators Market Research and Analysis by End-users

The Report Covers
  • Comprehensive research methodology of the Implantable Cardioverter Defibrillators market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Implantable Cardioverter Defibrillators market.
  • Insights about market determinants which are stimulating the Implantable Cardioverter Defibrillators market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbott Laboratories, Inc.
  • Biotronik SE & Co. KG
  • Cintas Corp.
  • Defibtech, LLC
  • General Electric Co.
  • Koninklijke Philips N.V.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Competitive Dashboard
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. Global Implantable Cardioverter Defibrillator Market by Product
5.1.1. Transvenous Implantable Cardioverter Defibrillator (T-ICDS)
5.1.2. Subcutaneous Implantable Cardioverter Defibrillator (S-ICDS)
5.2. Global Implantable Cardioverter Defibrillator Market by End-Users
5.2.1. Hospitals
5.2.2. Diagnostic Centers
5.2.3. Ambulatory Service
5.2.4. Homecare

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles
Abbott Laboratories, Inc.
Biotronik SE & Co. KG
Cintas Corp.
Defibtech, LLC
General Electric Co.
Koninklijke Philips N.V.
LivaNova PLC
Medtronic PLC
Nihon Kohden Corp.
Stryker Corp.
Note: Product cover images may vary from those shown
3 of 3
  • Abbott Laboratories, Inc.
  • Biotronik SE & Co. KG
  • Cintas Corp.
  • Defibtech, LLC
  • General Electric Co.
  • Koninklijke Philips N.V.
  • LivaNova PLC
  • Medtronic PLC
  • Nihon Kohden Corp.
  • Stryker Corp.
Note: Product cover images may vary from those shown
Adroll
adroll